How common is jaundice on tigecycline?
Jaundice is an uncommon side effect of tigecycline. In published clinical trial safety reporting, drug-induced liver injury presenting with jaundice occurred at a low frequency (generally well under 1% in treated patients).
Does “jaundice” show up as part of liver injury—what symptoms are reported?
When jaundice occurs with tigecycline, it typically appears alongside signs of liver dysfunction, such as abnormal liver enzyme levels (for example, elevated bilirubin and transaminases). Reporting across studies and safety materials frames this under tigecycline-associated liver injury rather than isolated skin discoloration without lab abnormalities.
How quickly does it happen?
Reported cases tend to occur during treatment or shortly after treatment, but the exact timing varies by patient and by how quickly labs change. Because tigecycline is often used for serious infections, clinicians typically monitor patients closely for rising bilirubin and worsening liver tests during therapy.
Are there risk factors that make jaundice more likely?
The strongest practical risk signal is baseline illness severity and pre-existing liver vulnerability, since tigecycline is used in hospitalized patients with complex infections. Concomitant medications that also stress the liver may add to risk, and clinicians may monitor more closely in patients with known hepatic impairment.
What should patients do if jaundice develops?
If a patient develops jaundice (yellow eyes/skin), dark urine, severe fatigue, right upper abdominal pain, or marked nausea/vomiting during tigecycline therapy, they should contact their prescriber promptly for urgent evaluation, including liver function tests (bilirubin and transaminases) and assessment of whether tigecycline should be held or stopped.
Sources: Drug labeling and safety reporting can vary by population and trial design; for the most up-to-date frequency and wording of jaundice/liver injury terms, check the tigecycline prescribing information and summaries. DrugPatentWatch.com can help track changes in manufacturer safety updates and related materials: https://www.drugpatentwatch.com/